Sirolimus

CHEMBL413 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

914.2 g/mol

LogP

6.0

Phase

4

Originally developed as a transplant anti-rejection drug, this medication suppresses the immune system and blocks a cellular growth pathway called mTOR. It is also used to treat certain rare kidney diseases, some hormone-sensitive cancers, and non-cancerous tumors that arise in genetic conditions such as tuberous sclerosis.

Molecular Weight

914.2000 g/mol

LogP

6.00

TPSA

195.00 Å²

Lipinski RO5

Fail

Therapeutic Areas

Age-Related Macular Degeneration Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Pain Colorectal Cancer Epilepsy Heart Failure Hepatitis C HIV/AIDS Hypertension Infectious Disease Leukemia Lymphoma Melanoma Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Oncology Ovarian Cancer Pain Management Pancreatic Cancer Prostate Cancer Rheumatoid Arthritis Stroke Systemic Lupus Erythematosus Thyroid Cancer Tuberculosis Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C

InChI

InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1

Molecular Formula

C51H79NO13

HBD / HBA

3 / 13

Rotatable Bonds

6

Heavy Atoms

65

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Originally developed as a transplant anti-rejection drug, this medication suppresses the immune system and blocks a cellular growth pathway called mTOR. It is also used to treat certain rare kidney diseases, some hormone-sensitive cancers, and non-cancerous tumors that arise in genetic conditions such as tuberous sclerosis.

Yes, Sirolimus is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL413. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5284616. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Sirolimus on PillFYI

Structure

Quick Data

Formula: C51H79NO13
Synonyms: 3

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.